Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, characterized by a decline in cognitive function, behavioral changes, and functional impairment [1] [2] [3]. It primarily affects individuals in late middle age or old age, with symptoms worsening over time [2]. The disease involves the accumulation of amyloid-beta plaques and tau neurofibrillary tangles in the brain, leading to neuronal loss and brain atrophy [2] [5].

According to www.iAsk.Ai - Ask AI:

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code G30.9 is used to classify Alzheimer's disease when no specific details or subtypes are provided [1] [2] [4]. This code is billable and specific, meaning it can be used for reimbursement purposes [2]. The 2025 edition of ICD-10-CM G30.9 became effective on October 1, 2024 [2].

Diagnosis of Alzheimer's disease, even when unspecified (G30.9), typically involves a comprehensive clinical evaluation by a healthcare professional [1]. Key diagnostic criteria and considerations include:

• Cognitive Decline: Persistent and progressive decline in cognitive functions such as memory, problem-solving, and judgment [1].
• Behavioral Changes: Observable shifts in personality and behavior, including increased irritability, anxiety, depression, or social withdrawal [1].
• Functional Impairment: Difficulties in performing daily activities like managing finances, cooking, or personal hygiene [1].
• Language Difficulties: Challenges with word-finding, following conversations, or understanding language [1].
• Disorientation: Episodes of confusion regarding time, place, or familiar environments [1].
• Memory Loss: Significant impairment, particularly in short-term memory, affecting the ability to retain new information [1].
• Neurological Examination: Clinical evaluation and neuropsychological testing to confirm cognitive deficits [1].
• Exclusion of Other Causes: Ruling out other potential causes of dementia-like symptoms through appropriate testing and medical history review [1].
• Imaging Studies: Brain imaging (MRI or CT scans) may show characteristic changes, though they are not definitive for diagnosis [1].
• Family History: Consideration of a family history of similar symptoms or diagnoses [1].

For the management and treatment of Alzheimer's disease (ICD-10 code G30.9), several Current Procedural Terminology (CPT) codes may be applicable for billing and documentation of services [1] [3]:

• CPT 99201-99215: Evaluation and Management (E/M) services for new or established patients, including office or outpatient visits [1].
• CPT 96116: Neurobehavioral status exam, assessing thinking, reasoning, and judgment for diagnosis and treatment planning [1].
• CPT 96132-96133: Neuropsychological testing evaluation services to assess cognitive function [1].
• CPT 99483: Assessment and care planning for patients with cognitive impairment, including Alzheimer's disease, which involves a comprehensive care plan [1] [3]. This code requires specific elements such as an independent historian, multidimensional assessment (cognition, function, safety), evaluation of neuropsychiatric symptoms, medication review, and caregiver needs assessment [3]. It can be reported once every 180 days [3].
• CPT 99324-99337: Domiciliary, rest home, or custodial care services for patients requiring ongoing care in these settings [1].
• CPT 99341-99350: Home visit services for patients unable to visit a healthcare facility [1].

Recent research has focused on drug treatments for Alzheimer's disease. Donepezil and Memantine are two FDA-approved pharmacological treatments [3] [5]. Donepezil is a cholinesterase inhibitor that increases acetylcholine availability, while Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist that regulates glutamate activity [5]. A comprehensive causal inference study using real-world data found that the combined use of Donepezil and Memantine significantly increased the probability of five-year survival for Alzheimer's disease patients compared to no drug treatment or monotherapy [5]. Specifically, the combined use increased the five-year survival probability by 0.050 (6.4%) compared to no drug treatment, 0.049 (6.3%) compared to Memantine monotherapy, and 0.065 (8.3%) compared to Donepezil monotherapy [5]. This study also identified a significant beneficial additive drug-drug interaction effect of 0.064 [5]. These findings suggest that adopting combined treatment could extend the lives of a significant number of AD patients [5].

Beyond these established treatments, newer therapies like lecanemab-irmb (Leqembi) have received traditional FDA approval for the treatment of Alzheimer's disease [5] [6]. Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that targets aggregated soluble (protofibril) and insoluble forms of amyloid beta [6]. It is indicated for patients with mild cognitive impairment or mild dementia stage of the disease [6]. Clinical trials have shown that lecanemab reduces amyloid beta plaques and slows clinical decline on measures of cognition and function [6]. However, it is associated with adverse events, including amyloid-related imaging abnormalities (ARIA), which can manifest as brain swelling (ARIA-E) or microhemorrhage (ARIA-H) [6]. Testing for apolipoprotein E ε4 (ApoE ε4) status is recommended prior to treatment initiation due to a higher incidence of ARIA in ApoE ε4 homozygotes [6].